Conference Coverage

EASD: Alirocumab lipid-lowering benefits extend to patients with high-risk diabetes

Publish date: October 1, 2015

 

AT EASD 2015

References

The potential for alirocumab to reduce cardiovascular events will be investigated in the large, phase III ODYSSEY Outcomes study. This trial is currently recruiting and aims to accrue around 18,000 high-risk patients including those with diabetes. The study is projected to complete by the end of 2017.

Pages

Recommended Reading

HbA1c aids prediction of atherosclerotic CVD
MDedge Cardiology
High-calorie American diet causes insulin resistance within days
MDedge Cardiology
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin
MDedge Cardiology
Long-acting basal insulin controls HbA1c as well as glargine
MDedge Cardiology
No difference in long-term cost for diabetes treatment with bariatric surgery
MDedge Cardiology
EASD: SGLT2 inhibitor empagliflozin cuts CV risk in patients with type 2 diabetes
MDedge Cardiology
Empagliflozin’s triumph respins FDA’s diabetes drug mandate
MDedge Cardiology
Long-acting insulin degludec – and degludec combo drug – win FDA nod
MDedge Cardiology
Severity of obesity matters in pediatric population
MDedge Cardiology
EASD: Diabetes doubles death risk from many causes
MDedge Cardiology